News
OKYO
1.500
+2.70%
0.039
Weekly Report: what happened at OKYO last week (0422-0426)?
Weekly Report · 2d ago
Weekly Report: what happened at OKYO last week (0415-0419)?
Weekly Report · 04/22 11:18
Weekly Report: what happened at OKYO last week (0408-0412)?
Weekly Report · 04/15 11:09
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease. OKYO is rescheduling a Key Opinion Leader event scheduled for April 2024 to May 2024. The Company plans to present at upcoming ophthalmic conferences.
Forward News · 04/08 23:00
Weekly Report: what happened at OKYO last week (0401-0405)?
Weekly Report · 04/08 11:15
OKYO PHARMA ANNOUNCES UPCOMING PRESENTATION OF OK-101 PHASE 2 DATA FOR DRY EYE DISEASE AT EYECELERATOR 2024, A PARTNER MEETING OF THE AMERICAN SOCIETY FOR CATARACT AND REFRACTIVE SURGERY
Reuters · 04/02 11:00
Weekly Report: what happened at OKYO last week (0325-0329)?
Weekly Report · 04/01 11:13
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Landos Biopharma, Inc. Shares jumped 171.2% to $21.70 on Monday. AbbVie and Landos signed a definitive agreement to acquire the company. Altamira Therapeutics Ltd. Shares climbed 70.1% after falling around 22% on Friday. GameStop Corp. Shares rose 8.4% after the company announced a separation.
Benzinga · 03/25 18:44
Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack
On the Move Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack. Etao International down 96% on account of reverse stock split and share restructure announced last week. Bitcoin Depot down 11% on Q4 earnings release.
Seeking Alpha · 03/25 12:41
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Salarius Pharmaceuticals, Inc. Shares rose sharply in pre-market trading following fourth-quarter results. The company posted a net loss of $0.9 million for the fourth quarter. Canopy Growth Corporation and Esperion Therapeutics were among the other stocks moving in the day's trading.
Benzinga · 03/25 12:03
Weekly Report: what happened at OKYO last week (0318-0322)?
Weekly Report · 03/25 11:15
Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study
OKYO Pharma Limited says OK-101 showed a statistically significant reduction in ocular pain. The company says the ophthalmic solution is being tested in patients with dry eye disease. OK- 101 also showed significant improvements in burning/stinging and blurred vision. The drug is in Phase 2 of a clinical trial.
Benzinga · 03/22 15:53
HC Wainwright & Co. Maintains Buy on OKYO Pharma, Raises Price Target to $7
Benzinga · 03/22 15:05
Analysts Offer Insights on Healthcare Companies: Apyx Medical (APYX) and OKYO Pharma Limited Sponsored ADR (OKYO)
TipRanks · 03/22 13:00
OKYO Pharma gains after positive results from Phase 2 dry eye disease trial
OKYO Pharma gains after positive results from Phase 2 dry eye disease trial. Shares of OKyO Pharma rose more than 7% in premarket trade on Friday. OK-101 ophthalmic solution showed significant improvements in dry eye symptoms. OKYO shares rose +7.38% to $1.89.
Seeking Alpha · 03/22 12:32
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
OKYO Pharma Limited will host a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss the findings of the Phase 2 trial of OK-101 in dry eye disease. The company's Phase 2 OK- 101 efficacy data will be released on March 22nd, 2024. The event will feature Jay Pepose, MD, PhD and Anat Galor, MD. OKYO is developing innovative therapies for the treatment of inflammatory dry eye diseases.
Forward News · 03/21 11:00
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
OKYO Pharma Limited will release new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease on March 22, 2024. The company will also host a Key Opinion Leader (KOL) event to discuss the findings. OKyO Pharma is developing innovative therapies for the treatment of inflammatory dry eye diseases. OK- 101 showed statistically significant drug effects in the study.
Forward News · 03/20 11:00
Weekly Report: what happened at OKYO last week (0311-0315)?
Weekly Report · 03/18 11:14
Weekly Report: what happened at OKYO last week (0304-0308)?
Weekly Report · 03/11 11:10
Weekly Report: what happened at OKYO last week (0226-0301)?
Weekly Report · 03/04 11:13
More
Webull provides a variety of real-time OKYO stock news. You can receive the latest news about OKYO PHARMA LTD through multiple platforms. This information may help you make smarter investment decisions.
About OKYO
OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The Company operates through the research and development of biotechnological and pharmaceutical products segment. The Company’s technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Company’s wholly owned subsidiary is OKYO Pharma US Inc.